Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 2074-2081

  Landersdorfer, Cornelia B ^a,f   Kinzig, Martina ^a   Hennig, Friedrich F ^b   Bulitta, Jürgen B ^a,f   Holzgrabe, Ulrike ^c   Drusano, George L ^d   Sörgel, Fritz ^a,e   Gusinde, Johannes ^b  

^a Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d ORDWAY RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CLINDAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; CANCELLOUS BONE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OSTEOMYELITIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TOTAL HIP PROSTHESIS;

AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ARTHROPLASTY, REPLACEMENT, HIP; AZA COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FEMUR; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; QUINOLINES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 66149153409     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01056-08     Document Type: Article

References (55)

1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
2. Aminimanizani, A., P. Beringer, and R. Jelliffe. 2001. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin. Pharmacokinet. 40:169-187. (Pubitemid 32324449)
3. Andersson, M. I., and A. P. MacGowan. 2003. Development of the quinolones. J. Antimicrob. Chemother. 51(Suppl. 1):1-11. (Pubitemid 36622099)
4. Barry, A. L., R. N. Jones, C. Thornsberry, L. W. Ayers, E. H. Gerlach, and H. M. Sommers. 1984. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob. Agents Chemother. 25:633-637. (Pubitemid 14101158)
5. Beal, S. L., A. J. Boeckmann, L. B. Sheiner, et al. 1999. NONMEM user's guides, version 5. University of California at San Francisco, San Francisco, CA.
6. Bijl, W., and R. A. Janknegt. 1993. Single-dose versus 3-day prophylaxis with ciprofloxacin in transurethral surgery. A clinical trial. Urol. Int. 51:73-78. (Pubitemid 23230879)
7. Blumer, J. L., M. D. Reed, E. L. Kaplan, and G. L. Drusano. 2005. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group A streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling. Pediatrics 116:927-932. (Pubitemid 44542820)
8. Bustamante, C. I., G. L. Drusano, R. C. Wharton, and J. C. Wade. 1987. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob. Agents Chemother. 31:632-634.
9. Chin, N. X., D. C. Brittain, and H. C. Neu. 1986. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob. Agents Chemother. 29:675-680.
10. Chin, N. X., and H. C. Neu. 1984. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 25:319-326. (Pubitemid 14166483)
11. Cowin, S. C. 2001. Bone mechanics handbook. CRC Press, Boca Raton, FL.
12. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
13. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPTII user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
14. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat. Rev. Microbiol. 2:289-300.
15. Drusano, G. L., S. L. Preston, C. Fowler, M. Corrado, B. Weisinger, and J. Kahn. 2004. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 189:1590-1597. (Pubitemid 38648286)
16. Drusano, G. L., S. L. Preston, M. H. Gotfried, L. H. Danziger, and K. A. Rodvold. 2002. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46:586-589. (Pubitemid 34087223)
17. Drusano, G. L., S. L. Preston, M. Van Guilder, D. North, M. Gombert, M. Oefelein, L. Boccumini, B. Weisinger, M. Corrado, and J. Kahn. 2000. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob. Agents Chemother. 44:2046-2051. (Pubitemid 30484425)
18. Eliopoulos, G. M., A. Gardella, and R. C. Moellering, Jr. 1984. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob. Agents Chemother. 25:331-335.
19. European Committee on Antimicrobial Susceptibility Testing. 19 June 2008, posting date. Fluoroquinolones - EUCAST clinical MIC breakpoints. ESCMID, Basel, Switzerland.
20. Foster, J. K., J. R. Lentino, R. Strodtman, and C. DiVincenzo. 1986. Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies. Antimicrob. Agents Chemother. 30:823-827.
21. Gentry, L. O., and G. G. Rodriguez. 1990. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob. Agents Chemother. 34:40-43. (Pubitemid 20019961)
22. Greenberg, R. N., D. J. Kennedy, P. M. Reilly, K. L. Luppen, W. J. Weinandt, M. R. Bollinger, F. Aguirre, F. Kodesch, and A. M. Saeed. 1987. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob. Agents Chemother. 31:151-155.
23. Hardy, D. J., R. N. Swanson, D. M. Hensey, N. R. Ramer, R. R. Bower, C. W. Hanson, D. T. Chu, and P. B. Fernandes. 1987. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob. Agents Chemother. 31:1768-1774. (Pubitemid 17157641)
24. Hoogkamp-Korstanje, J. A. 1987. Treatment of chronic postsurgical osteomyelitis with ciprofloxacin. Pharm. Weekbl. Sci. 9(Suppl.):S90-S92.
25. Hudson, M. C., W. K. Ramp, N. C. Nicholson, A. S. Williams, and M. T. Nousiainen. 1995. Internalization of Staphylococcus aureus by cultured osteoblasts. Microb. Pathog. 19:409-419. (Pubitemid 26091044)
26. Landersdorfer, C. B., J. B. Bulitta, M. Kinzig, U. Holzgrabe, and F. Sörgel. 2009. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin. Pharmacokinet. 48:89-124.
27. Lew, D. P., and F. A. Waldvogel. 2004. Osteomyelitis. Lancet 364:369-379.
28. Lew, D. P., and F. A. Waldvogel. 1999. Use of quinolones in osteomyelitis and infected orthopaedic prosthesis. Drugs 58(Suppl. 2):85-91. (Pubitemid 29500093)
29. Lunn, D. J., J. Wakefield, A. Thomas, N. G. Best, and D. J. Spiegelhalter. 1999. Pkbugs user guide, version 1.1. Imperial College, London, United Kingdom.
30. Malincarne, L., M. Ghebregzabher, M. V. Moretti, A. M. Egidi, B. Canovari, G. Tavolieri, D. Francisci, G. Cerulli, and F. Baldelli. 2006. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J. Antimicrob. Chemother. 57:950-954.
31. Mandell, W., and H. C. Neu. 1986. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob. Agents Chemother. 29:852-857.
32. Manek, N., J. M. Andrews, and R. Wise. 1986. In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob. Agents Chemother. 30:330-332.
33. Massias, L., P. Buffe, B. Cohen, Y. Cudennec, P. Gehanno, O. Sterkers, and R. Farinotti. 1994. Study of the distribution of oral ciprofloxacin into the mucosa of the middle ear and the cortical bone of the mastoid process. Chemotherapy 40(Suppl. 1):3-7. (Pubitemid 24293491)
34. Metallidis, S., N. Charokopos, J. Nikolaidis, E. Alexiadou, G. Lazaraki, E. Koumentaki, A. Tsona, G. Theodoridis, and P. Nikolaidis. 2006. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery. Int. J. Antimicrob. Agents 28:428-432. (Pubitemid 44636183)
35. Metallidis, S., D. Topsis, J. Nikolaidis, E. Alexiadou, G. Lazaraki, L. Grovaris, A. Theodoridou, and P. Nikolaidis. 2007. Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty. J. Chemother. 19:682-687.
36. Mouton, J. W., U. Theuretzbacher, W. A. Craig, P. M. Tulkens, H. Derendorf, and O. Cars. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237.
37. Nix, D. E., T. J. Cumbo, P. Kuritzky, J. M. DeVito, and J. J. Schentag. 1987. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. Am. J. Med. 82:146-153.
38. Petitjean, O., M. Tod, and K. Louchahi. 1995. Influence of methodological aspects on tissue drug concentration estimation. J. Pharm. Biomed. Anal. 13:817-822.
39. Schwarz, M., R. Isenmann, J. Thomsen, W. Gaus, and H. G. Beger. 2001. Efficacy of oral ofloxacin for single-dose perioperative prophylaxis in general surgery - a controlled randomized clinical study. Langenbecks Arch. Surg. 386:397-401. (Pubitemid 33140745)
40. Siefert, H. M., A. Domdey-Bette, K. Henninger, F. Hucke, C. Kohlsdorfer, and H. H. Stass. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43(Suppl. B):69-76. (Pubitemid 29231796)
41. Simon, N., E. Sampol, J. Albanese, C. Martin, P. Arvis, S. Urien, B. Lacarelle, and B. Bruguerolle. 2003. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Clin. Pharmacol. Ther. 74:353-363. (Pubitemid 37222856)
42. Smith, S. M. 1986. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin- resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 29:325-326. (Pubitemid 16162948)
43. Smith, S. M., and R. H. Eng. 1985. Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 27:688-691.
44. Spiegelhalter, D. J., A. Thomas, and N. G. Best. 2003. WinBUGS version 1.4 user manual. Medical Research Council Biostatics Unit, Cambridge, United Kingdom.
45. Stass, H., A. Dalhoff, D. Kubitza, and U. Schuhly. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065. (Pubitemid 28363093)
46. Stass, H., and D. Kubitza. 1999. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J. Antimicrob. Chemother. 43(Suppl. B):83-90. (Pubitemid 29231798)
47. Stass, H., D. Kubitza, A. Halabi, and H. Delesen. 2002. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br. J. Clin. Pharmacol. 53:232-237. (Pubitemid 34226965)
48. Stass, H., D. Kubitza, and U. Schuhly. 2001. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin. Pharmacokinet. 40(Suppl. 1):1-9. (Pubitemid 32295676)
49. Stratton, C. W., C. Liu, and L. S. Weeks. 1987. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. Antimicrob. Agents Chemother. 31:1210-1215. (Pubitemid 17157601)
50. Trampuz, A., and A. F. Widmer. 2006. Infections associated with orthopedic implants. Curr. Opin. Infect. Dis. 19:349-356. (Pubitemid 43982507)
51. Van Bambeke, F., J. M. Michot, J. Van Eldere, and P. M. Tulkens. 2005. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11:256-280. (Pubitemid 40443832)
52. Wise, R., J. M. Andrews, G. Marshall, and G. Hartman. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43:1508-1510. (Pubitemid 29259357)
53. Wise, R., C. Cross, and J. M. Andrews. 1984. In vitro activity of CGP 31523A, a broad-spectrum cephalosporin, in comparison with those of other agents. Antimicrob. Agents Chemother. 26:876-880.
54. Wittman, D. H., and E. Kotthaus. 1986. Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage. Infection 14(Suppl. 4):S270-S273.
55. Zhanel, G. G., K. Ennis, L. Vercaigne, A. Walkty, A. S. Gin, J. Embil, H. Smith, and D. J. Hoban. 2002. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62:13-59. (Pubitemid 34169425)